statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

AN2 Therapeutics just upgraded at JMP Securities, here's why

AN2 Therapeutics, Inc. (ANTX) has disclosed a new risk, in the Innovation / R&D category. AN2 Therapeutics, Inc. faces significant business risk as...

AN2 Therapeutics' High-Stakes Gamble: Navigating FDA Approval for Epetraborole Amid Clinical Trial Uncertainties

AN2 Therapeutics GAAP EPS of -$0.57 beats by $0.17...

AN2 Therapeutics GAAP EPS of -$0.57 beats by $0.17

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
ANTX stock results show that AN2 Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
The post ANTX...

ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q4 2023

AN2 Therapeutics reports Q4 EPS (57c), consensus (75c)

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today...

AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights

Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results PR Newswire DURHAM...

Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AN2 Therapeutics, Inc. ( AN2 or the Company ) (NASDAQ: ANTX). Such investors are...

AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley and is headquartered in Menlo Park, CA.

Watchers	293
52-Wk Low	$2.20
52-Wk High	$22.22

Volume	30.00
52-Wk High	$22.22
52-Wk Low	$2.20

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.62	--	--	N/A
Q4'23	-$0.74	-$0.57	22.55%	BEAT
Q3'23	-$0.65	-$0.65	-0.39%	MISSED
Q2'23	-$0.85	-$0.81	4.99%	BEAT
Q1'23	-$0.66	-$0.79	-20.15%	MISSED

ANTX AN2 Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals